Abstract:
Objectives: To report the sexual functional outcomes of vaginal dilation therapy in Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome patients. Methods: From March 2020 to February 2023, 97 MRKH syndrome patients performed vaginal dilation therapy with guidance from Peking Union Medical College Hospital, and 45 of them engaged in penetrative intercourse and were included in this prospective cohort study. The Chinese version of female sexual function index (FSFI) was used to assess sexual function. Functional success was defined as FSFI>23.45. Forty age-matched healthy women were selected as controls. Kaplan-Meier survival analysis was used to calculate the median time to success. Pearson correlation analysis was used to explore the relationship between neovagina length and sexual function. Complications were collected using follow-up questionnaires. Results: The functional success rate of vaginal dilation therapy was 89% (40/45) with a median time to success of 4.3 months (95%CI: 3.0-6.1 months). Compared to controls, MRKH syndrome patients had significantly lower scores in the orgasm domain (4.72±1.01 vs 4.09±1.20; P=0.013) and pain domain (5.03±0.96 vs 4.26±0.83; P<0.001). However, there were no significant differences in the FSFI total score (26.77±2.70 vs 26.70±2.33; P=0.912), arousal domain (4.43±0.77 vs 4.56±0.63; P=0.422) and satisfaction domain (4.88±0.98 vs 4.65±0.86; P=0.269) between MRKH syndrome patients and controls. MRKH syndrome patients had significantly higher scores in the desire domain (3.33±0.85 vs 3.95±0.73; P<0.001) and lubrication domain (4.37±0.56 vs 5.20±0.67; P<0.001). The prevalence of sexual dysfunction in MRKH patients was non-inferior to controls: low desire [3% (1/40) vs 23% (9/40); P=0.007], arousal disorder [3% (1/40) vs 3% (1/40); P>0.999], lubrication disorder [5% (2/40) vs 25% (10/40); P=0.012], orgasm disorder [40% (16/40) vs 20% (8/40); P=0.051], sexual pain [30% (12/40) vs 15% (6/40); P=0.108]. Conclusions: MRKH syndrome patients undergoing non-invasive vaginal dilation therapy could achieve satisfactory sexual life. Given its high functional success rate and slight complication, vaginal dilation therapy should be recommended as the first-line option, reducing the need for unnecessary surgeries.
目的: 评估顶压法人工阴道成形术的Mayer-Rokitansky-Küster-Hauser(MRKH)综合征患者的性功能、功能学成功率及并发症。 方法: 本研究为前瞻性队列研究,选取2020年3月至2023年2月于北京协和医院行顶压法人工阴道成形术的MRKH综合征患者共97例,其中45例顶压治疗开始后有阴茎插入式性生活被纳入本研究(即观察组)。采用经中文验证的女性性功能指数量表(FSFI)对患者性功能进行评估,采用FSFI总分>23.45分为功能学成功标准;同时选择40例年龄匹配的正常妇女作为对照组。采用Kaplan-Meier法计算顶压开始至成功所需的时长。采用Pearson相关性分析计算阴道长度与FSFI评分之间的关系。通过随访问卷记录患者顶压过程中出现的并发症。 结果: 89%(40/45)的观察组MRKH综合征患者顶压后达到功能学成功标准,成功所需的中位时长为4.3个月(95%CI为3.0~6.1个月)。与对照组相比,虽然观察组的性高潮评分[分别为(4.72±1.01)、(4.09±1.20)分;P=0.013]和疼痛程度评分[分别为(5.03±0.96)、(4.26±0.83)分;P<0.001]低于对照组,但观察组在FSFI总分[(26.77±2.70)、(26.70±2.33)分;P=0.912]、性欲望评分[(3.33±0.85)、(3.95±0.73)分;P<0.001]、性唤起评分[(4.43±0.77)、(4.56±0.63)分;P=0.422]、阴道润滑程度评分[(4.37±0.56)、(5.20±0.67)分;P<0.001]和满意度评分[(4.88±0.98)、(4.65±0.86)分;P=0.269]方面均不劣于对照组。功能学成功的观察组患者各项性功能障碍的发生率与对照组比较显示,性欲低下[分别为3%(1/40)、23%(9/40);P=0.007]和阴道润滑障碍[分别为5%(2/40)、25%(10/40);P=0.012]的发生率显著低于对照组,而性唤起障碍[均为3%(1/40);P>0.999]、性高潮障碍[分别为40%(16/40)、20%(8/40);P=0.051]、性交痛[分别为30%(12/40)、15%(6/40);P=0.108]的发生率无显著差异。顶压过程中出现的并发症主要包括轻中度阴道疼痛(67%,30/45)、阴道点滴出血(33%,15/45)和尿路刺激征(9%,4/45)。 结论: 无创的顶压法人工阴道成形术成功率高,并发症轻微,患者性生活满意度高。应当推广顶压法作为MRKH综合征患者阴道重建的一线治疗方案,减少不必要的手术。.